Berhanu Kibret

Berhanu Kibret, BPharm, MS, PhD, is an Instructor in the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy

Headshot of Berhanu KibretBerhanu Kibret, BPharm, MS, PhD
Instructor, Department of Pharmaceutical Sciences

20 Penn StreetBaltimore, MD 21201HSF II, 559

Phone: 410-706-7059Email: bkibret@rx.umaryland.edu

Postdoctoral, PhD, MS – Not currently recruiting

Education

  • Postdoctoral Fellow, neuroimmune and behavioral effects of cannabinoid CB2 receptors in neuropsychiatric and neurodegenerative disorders, William Paterson University, Wayne, New Jersey
  • PhD, Pharmacology, Addis Ababa University, Addis Ababa, Ethiopia
  • MSc, Pharmacology, Addis Ababa University, Addis Ababa, Ethiopia
  • BSc, Pharmacy, Jimma University, Jimma, Ethiopia

Research Interests

Role of the endocannabinoid system (ECS) in neuropsychiatric and neurodegenerative disorders with a nuanced emphasis on unraveling the intricate involvement of neuronal and glial type 2 cannabinoid (CB2) receptors in neuroimmune and behavioral effects of drugs of abuse.

Current Projects

Role of neuronal and glial CB2 receptors in neuroimmune and behavioral effects of drugs of abuse. 

Publications

  1. Roberts A, Christian M, Dilone LN, Nelson N, Endrino MJ, Kneebone A, Embaby S, Fernandez J, Liu Q-R, Onaivi ES and Kibret BG (2023) Alcohol induced behavioral and immune perturbations are attenuated by activation of CB2 cannabinoid receptors. Adv. Drug Alcohol Res. 3:11602
  2. Kibret BG, Roberts A, Kneebone A, Embaby S, Fernandez J, Liu QR, Onaivi ES (2023). Cannabinoid CB2 receptors modulate alcohol induced behavior, and neuro-immune dysregulation in mice. Behav Brain Res. 448:114439
  3. Kibret BG, Canseco-Alba A, Onaivi ES and Engidawork E (2023). Crosstalk between the endocannabinoid and mid-brain dopaminergic systems: Implication in dopamine dysregulation. Front. Behav. Neurosci. 17:1137957.
  4. Ishiguro H, Kibret BG, Horiuchi Y, Onaivi ES (2022). Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders. Front. Psychiatry. 13: 828895.
  5. Kibret BG, Patel S, Niezgoda J, Guns W, Niezgoda J, Gopalakrishnan S, Baban B, Cubillos P, Villeneuve D, Kumar P. Evidence-based Potential Therapeutic Applications of Cannabinoids in Wound Management. Adv Skin Wound Care. 35: 1-7.
  6. Kibret BG, Ishiguro H, Onaivi ES (2022). New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders. Int J Mol Sci. 23(2): 975.
  7. Geresu B, Canseco-Alba A, Sanabria B, Lin Z, Liu QR, Onaivi ES, Engidawork E (2019). Involvement of CB2 Receptors in the Neurobehavioral Effects of Catha Edulis (Vahl) Endl. (Khat) in Mice. Molecules. 24(17): 3164.
  8. Geresu B, Belton J, Kumar P (2017). Cannabinoid-Induced Hyperemesis Syndrome. 27th Annual Symposium on the Cannabinoids, International Cannabinoid Research Society, Montreal, QC, Canada, P3-45.
  9. Belton J, Geresu B, Knight S, Catuccio E and Kumar P (2017). Analysis of patients experiencing toxic effects from synthetic cannabinoids. 27th Annual Symposium on the Cannabinoids, International Cannabinoid Research Society, Montreal, QC, Canada, P1-15.
  10. Geresu B, Onaivi E, Engidawork E (2016). Behavioral evidence for the interaction between cannabinoids and Catha edulis F. (Khat) in mice. Brain Res. 1648: 333-338.
  11. Geresu B (2015). Khat (Catha edulis F.) and cannabinoids: Parallel and contrasting behavioral effects in preclinical and clinical studies. Pharmacol Biochem Behav. 138: 164-173.
  12. Geresu B, Engidawork E (2010). Catha edulis F. (Khat) Reverses Haloperidol But Not Morphine Induced Motor Deficits Following Acute and Sub-acute Administration in Mice. Ethiop Pharm J. 28(2): 117-130.